UnknownNot Applicable

Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies

China427 participantsStarted 2023-01-06

Plain-language summary

The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against Metallo-β-lactamases (MBL) producing Enterobacterales in vivo. The investigators then use CRISPR/Cas9 technology to remove Enterobacteriaceae bacteria resistance and virulence genes

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects clinically suspected of infection caused by Enterobacterales * Subjects with bloodstream infection by MBL-producing Enterobacterales Exclusion Criteria: * Infections caused by viruses, fungi, atypical pathogens, and other non-Enterobacteriaceae bacteria * subjects who are unwilling to enter the research group

What they're measuring

30-day all-cause mortality

Timeframe: two years

clinical failure at day 14

Timeframe: two years

length of stay after diagnosis

Timeframe: two years

Trial details

NCT IDNCT05850871

SponsorQianfoshan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-31

Contact for this trial

Mingju Hao, Doctor

8613012995730 haomingju@163.com

View on ClinicalTrials.gov More Carbapenem-Resistant Enterobacteriaceae Infection trials